ライフサイエンスコーパス: combined immunodeficiency

1 capsules of SCID mice (ie, mice with severe combined immunodeficiency).

2 mbined immunodeficiency, Omenn syndrome, and combined immunodeficiency.

3 tenuated MM tumor growth in mice with severe combined immunodeficiency.

4 who displayed an unusual progressive form of combined immunodeficiency.

5 inflammatory bowel disease-like disorder and combined immunodeficiency.

6 s with gene therapy for ADA-deficient severe combined immunodeficiency.

7 1-null mutant mice on a background of severe combined immunodeficiency.

8 myelokathexis (WHIM) syndrome, a human rare combined immunodeficiency.

9 idered LCK a candidate gene in patients with combined immunodeficiency.

10 rigel, and formed tumors in mice with severe combined immunodeficiency.

11 assays in nonobese diabetic mice with severe combined immunodeficiency.

12 ch is mutated in humans with X-linked severe combined immunodeficiency.

13 subsequently received a diagnosis of severe combined immunodeficiency.

14 ciency is associated with a novel variant of combined immunodeficiency.

15 vels of IgE are features of some variants of combined immunodeficiency.

16 process defective in human and mouse severe combined immunodeficiency.

17 infant hospitalized in Minnesota with severe combined immunodeficiency.

18 sensitivity to ionizing radiation and severe combined immunodeficiency.

19 is defective in humans with X-linked severe combined immunodeficiency.

20 ns and null mutations in mice lead to severe combined immunodeficiency.

21 h protection occurred without causing severe combined immunodeficiency.

22 erize an inflammatory disease evocative of a combined immunodeficiency.

23 ations associated with multiple atresia with combined immunodeficiency.

24 om 9 patients with genetically confirmed PNP-combined immunodeficiency, 10,000 DBS samples from healt

25 ated in human radiosensitive T(-)B(-) severe combined immunodeficiency, a syndrome characterized by t

26 ed with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and set out to eval

27 ast, 39 adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) patients have been

28 cult' conditions [adenosine deaminase-severe combined immunodeficiency (ADA-SCID), major histocompati

29 at destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often referred to

30 denosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-Bodian-D

31 order of purine metabolism leading to severe combined immunodeficiency (ADA-SCID).

32 ify the genetic alteration in a patient with combined immunodeficiency and characterize human caspase

33 ecessive CD70 deficiency is a novel cause of combined immunodeficiency and EBV-associated diseases, r

34 l case of an RSV-infected infant with severe combined immunodeficiency and effectively no adaptive im

35 allosal agenesis, cataracts, cardiomyopathy, combined immunodeficiency and hypopigmentation.

36 hese features are consistent with the severe combined immunodeficiency and mild extraimmunological sy

37 oal of defining the true incidence of severe combined immunodeficiency and providing early treatment

38 patients presented from early childhood with combined immunodeficiency and severe autoimmune disease.

39 ted disorders, including MIA associated with combined immunodeficiency and very early onset inflammat

40 jected intraperitoneally (ie, in CB17 severe combined immunodeficiencies) and significantly increased

41 osa-associated lymphoid tissue 1 (MALT1) for combined immunodeficiencies, and tetratricopeptide repea

42 osis of adenosine deaminase-deficient severe combined immunodeficiency, and consanguinity were associ

43 Background Combined immunodeficiencies are marked by inborn errors

44 Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimmunity a

45 y reported a novel syndrome characterized by combined immunodeficiency associated with severe develop

46 lifornia established the incidence of severe combined immunodeficiency at 1 in 66,250 live births.

47 heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice.

48 given intranasally or i.p. to newborn severe combined immunodeficiency-beige mice exposed to 90% O2 f

49 C.B.-17 severe combined immunodeficiency-beige mice were transplanted w

50 ridium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the parasites

51 t is a common finding in infants with severe combined immunodeficiency but is not typically observed

52 Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 defects

53 overy occurred in VLP-dosed mice with severe combined immunodeficiency, but not in wild-type mice dep

54 T-cell deficiencies in patients with severe combined immunodeficiency by replacing resident thymus c

55 ed via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in a syst

56 cy CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of aggres

57 Severe combined immunodeficiency can be caused by loss-of-funct

58 Profound combined immunodeficiency can present with normal number

59 tor of cytokinesis 8 (DOCK8) deficiency is a combined immunodeficiency caused by autosomal recessive

60 s emerged as a convincing therapy for severe combined immunodeficiency caused by ILR2G mutation (SCID

61 n dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency characterized by atopy, recurr

62 ations in DOCK8 have been reported to have a combined immunodeficiency characterized by cutaneous vir

63 DOCK8 mutations result in an inherited combined immunodeficiency characterized by increased sus

64 ytokine receptor subunit give rise to severe combined immunodeficiency characterized by lack of T and

65 Patients with a combined immunodeficiency characterized by normal number

66 ovirus incidence was compared between severe combined immunodeficiency children with (n = 10) and wit

67 on of disease phenotypes for X-linked severe combined immunodeficiency, chronic granulomatous disease

68 n dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency (CID) also classified as autos

69 Combined immunodeficiency (CID) is a T-cell defect frequ

70 Combined immunodeficiency (CID) is characterized by seve

71 Combined immunodeficiency (CID) refers to inborn errors

72 I1 and STIM1 genes that abolish SOCE cause a combined immunodeficiency (CID) syndrome that is accompa

73 onical NF-kappaBeta pathways, resulting in a combined immunodeficiency (CID) without endocrine or ect

74 truction that is sometimes associated with a combined immunodeficiency (CID), leading to increased su

75 o present with autologous circulating T-cell combined immunodeficiency (CID).

76 Combined immunodeficiencies (CIDs) and "atypical" SCID s

77 Combined immunodeficiencies (CIDs) are diseases of defec

78 Combined immunodeficiencies (CIDs) form a heterogeneous

79 this review we describe peculiarities about combined immunodeficiencies (CIDs) in the Middle East.

80 Further, the nonobese diabetic severe combined immunodeficiency common gamma chain knockout-bo

81 PNP-combined immunodeficiency complies with the criteria for

82 equivocal evidence that children with severe combined immunodeficiency could be cured by gene transfe

83 Newborn screening for severe combined immunodeficiency detects athymic patients, alth

84 The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and related dis

85 V-CTLs both in vitro and in vivo in a severe combined immunodeficiency disease (SCID) mouse model and

86 ead to an autosomal recessive form of severe combined immunodeficiency disease (SCID).

87 nt with WHIM syndrome, an autosomal dominant combined immunodeficiency disease caused by gain-of-func

88 PET experiments were performed in severe combined immunodeficiency disease mice inoculated with p

89 Patients with severe combined immunodeficiency disease who have matched sibli

90 Children with clinical features of combined immunodeficiencies, especially with early-onset

91 s with specific forms of PID, such as severe combined immunodeficiency, for over 10 years.

92 s of anti-CD3epsilon mAb treatment in severe combined immunodeficiency forms characterized by poor th

93 healthy donors were injected into NOD-severe combined immunodeficiency gammac(-/-) mice, followed by

94 Nonobese diabetic-severe combined immunodeficiency-gammac(-/-) mice were injected

95 ells proliferate in nonobese diabetes/severe combined immunodeficiency/gammac(null) mice under the in

96 tients with atypical presentations of severe combined immunodeficiency gene mutations presents an opp

97 nt advances and newborn screening for severe combined immunodeficiency, has resulted in improved outc

98 ts with adenosine deaminase deficient severe combined immunodeficiency have identified neutropenia, a

99 -infected humanized nonobese diabetic severe combined immunodeficiency (HU-NOD/SCID) mice were genera

100 prevented bone destruction in vivo in severe combined immunodeficiency-hu mice.

101 Last, treatment of severe combined immunodeficiency-human (SCID-hu) mice with esta

102 and engraftment in nonobese diabetic/severe combined immunodeficiency IL-2gamma(null) (NSG) mice com

103 We report here the cause of combined immunodeficiency in 4 patients from 2 different

104 tor ARTEMIS cause radiation-sensitive severe combined immunodeficiency in humans and may increase sus

105 in patients with MIA and MIA associated with combined immunodeficiency include abnormalities of enter

106 hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rgamma(null) mice

107 e immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 gammac receptor(

108 efore, we created a nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-gamma-n

109 on by transplanting nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-gamma-n

110 arly onset of bone marrow failure leading to combined immunodeficiency is associated with microcephal

111 eplacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Amaurosis

112 T cells in a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome (OS).

113 rowth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05).

114 lls, leading to increased survival of severe combined immunodeficiency mice after transplantation of

115 al liver cells into nonobese diabetic/severe combined immunodeficiency mice allows for the long-term

116 after subcutaneous transplantation in severe combined immunodeficiency mice and differentiated into S

117 d copper-DOTA-conatumumab was done in severe combined immunodeficiency mice bearing Colo205 xenograft

118 In female CB17 severe combined immunodeficiency mice bearing Colo205 xenograft

119 by PET and ex vivo biodistribution in severe combined immunodeficiency mice bearing H2009 tumor (huma

120 o experiments, 6- to 12-wk-old female severe combined immunodeficiency mice bearing M21 xenografts (h

121 4)-BBN: for in vivo GRPR blockade) in severe combined immunodeficiency mice bearing PC-3 xenografts.

122 n erythrocytes into nonobese diabetic/severe combined immunodeficiency mice extends blood circulation

123 s transplanted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapitulated

124 Finally, YT cells transplanted into severe combined immunodeficiency mice had an invasive behavior.

125 gnificantly prolonged the survival of severe combined immunodeficiency mice inoculated with LCLs.

126 ers in the injured skeletal muscle of severe combined immunodeficiency mice more effectively than CD5

127 Six nonobese diabetic severe combined immunodeficiency mice received transplanted hum

128 transplantation in Non-obese diabetic/severe combined immunodeficiency mice that the HAGE knockdown i

129 ion in xenotolerant nonobese diabetic/severe combined immunodeficiency mice through intrasplenic or i

130 ted nonobese diabetic background with severe combined immunodeficiency mice to assess suppressive fun

131 Nonobese diabetic/severe combined immunodeficiency mice transplanted with leukemi

132 The tumorigenicity of cells in severe combined immunodeficiency mice was augmented to a larger

133 nized urokinase plasminogen activator/severe combined immunodeficiency mice were used to establish ch

134 lanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significantly high

135 mproved survival of nonobese diabetic/severe combined immunodeficiency mice with HL-60 leukemia.

136 eased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and

137 nced MM cells were then injected into severe combined immunodeficiency mice, and tumor growth in s.c.

138 In a xenograft analysis of severe combined immunodeficiency mice, cisplatin also efficient

139 as not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the immune re

140 In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of human HCC

141 immunocompromised non-obese diabetic/severe combined immunodeficiency mice, supporting an oncogenic

142 ferent genogroup, are inoculated into severe combined immunodeficiency mice, the order of severity of

143 ffeensis strains were inoculated into severe combined immunodeficiency mice, the order of the severit

144 MB-231 cell-derived mammary tumors in severe combined immunodeficiency mice, we show here for the fir

145 s the tumorigenicity of A549 cells in severe combined immunodeficiency mice.

146 suppressed tumor xenograft growth in severe combined immunodeficiency mice.

147 nhibited cholangiocarcinoma growth in severe combined immunodeficiency mice.

148 ro and in engrafted nonobese diabetic-severe combined immunodeficiency mice.

149 the choroids of six nude rats and six severe combined immunodeficiency mice.

150 hen transplanted to nonobese diabetic/severe combined immunodeficiency mice.

151 ansfer, delayed diabetes onset in NOD.severe combined immunodeficiency mice.

152 the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice.

153 n PBMC cultures and in PBMC-engrafted severe combined immunodeficiency mice.

154 the skeletal muscle of dystrophic mdx/severe combined immunodeficiency mice.

155 agar assays and xenograft analysis of severe combined immunodeficiency mice.

156 leukemic cells into nonobese diabetic/severe combined immunodeficiency mice.

157 ty of streptozotocin-induced diabetic severe combined immunodeficiency mice.

158 -L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

159 subcutaneously into nonobese diabetic severe combined immunodeficiency mice.

160 day prior to graft implantation into severe combined immunodeficiency mice.

161 1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mice.

162 SCID (severe combined immunodeficiency) mice underwent left anterior

163 were performed in Mec-1-bearing SCID (severe combined immunodeficiency) mice, a new animal model of h

164 When xenografted into SCID (severe combined immunodeficiency) mice, the expression of muPAR

165 found in NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice.

166 blastomas in an orthotopic, xenogenic severe combined immunodeficiency model.

167 In human artery-severe combined immunodeficiency mouse chimeras, in which patie

168 lence in human skin xenografts in the severe combined immunodeficiency mouse model in vivo.

169 ly in infected skin xenografts in the severe combined immunodeficiency mouse model of VZV pathogenesi

170 Using a nonobese diabetic/severe combined immunodeficiency mouse model, those antibodies

171 ftment in NOD-SCID (nonobese diabetic-severe combined immunodeficiency) mouse myocardium increased ca

172 h experimental systemic infections of severe combined immunodeficiency Mus musculus with the bacteriu

173 ith a synthetic LAT gene bearing this severe combined immunodeficiency mutation.

174 cell lymphopenic infants had variant SCID or combined immunodeficiency (n = 6), genetic syndromes ass

175 he renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MSCs isol

176 +) progenitors into nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice resulted in th

177 Here, we show that nonobese diabetic severe combined immunodeficiency (NOD/SCID) beta(2) microglobul

178 nto immunodeficient nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice leads to the d

179 xpressing tumors in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with partially

180 transplanted into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice.

181 induced diabetes in nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice.

182 n transplanted into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) recipient mice, FA-

183 entified in patients and are associated with combined immunodeficiencies of varying severity.

184 ided into 3 main categories: T(-)B(-) severe combined immunodeficiency, Omenn syndrome, and combined

185 uses T(-)B(+) natural killer-positive severe combined immunodeficiency or T-cell lymphopenia with sev

186 ystem since it did not occur in nude, severe combined immunodeficiency, or T-cell depleted mice.

187 esent a model for radiation-sensitive severe combined immunodeficiency, our findings suggest that the

188 ons or autoimmunity, they represent profound combined immunodeficiency (P-CID), for which outcome dat

189 xpression of Bcl2 does not rescue the severe combined immunodeficiency phenotype in Ku70-deficient mi

190 We describe a pedigree affected by a severe combined immunodeficiency phenotype with absent T cells

191 lex are now recognized as the cause of novel combined immunodeficiency phenotypes, which all share ab

192 A 14-year-old boy with severe combined immunodeficiency presented three times to a med

193 of STAT1 can be associated with progressive combined immunodeficiency, quite distinct from the limit

194 eficiency presents with a varied spectrum of combined immunodeficiency, ranging from a T(-)B(-)NK(+)

195 ular, and clinical features of many types of combined immunodeficiencies remain unknown.

196 ntains a rare CD34(-) population with severe combined immunodeficiency-repopulating capacity.

197 ectasia and a class of Radiosensitive-Severe Combined Immunodeficiency (RS-SCID), respectively, funct

198 n therefore results in radiosensitive severe combined immunodeficiency (RS-SCID).

199 -lymphocyte-independent protection of severe combined immunodeficiency SCID mice from disseminated ca

200 A subgroup of severe combined immunodeficiencies (SCID) is characterized by l

201 , wild-type (WT) and C3H animals with severe combined immunodeficiency (SCID animals) were inoculated

202 on of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many other c

203 TEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular radiosensi

204 nd severely impaired dissemination in severe combined immunodeficiency (SCID) and immunocompetent mic

205 cell transplantation in children with severe combined immunodeficiency (SCID) and other primary immun

206 opulation-based newborn screening for severe combined immunodeficiency (SCID) and related disorders h

207 Severe combined immunodeficiency (SCID) and X-linked agammaglob

208 Severe combined immunodeficiency (SCID) arises from different g

209 Severe combined immunodeficiency (SCID) can be cured by using a

210 Severe combined immunodeficiency (SCID) carries a poor prognosi

211 g gene 1 (RAG1) deficiency results in severe combined immunodeficiency (SCID) caused by a complete la

212 Severe combined immunodeficiency (SCID) comprises a group of di

213 Severe combined immunodeficiency (SCID) comprises a heterogeneo

214 pathology of Omenn syndrome and leaky severe combined immunodeficiency (SCID) has not been previously

215 The inclusion of severe combined immunodeficiency (SCID) in a Europe-wide screen

216 cular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans.

217 Severe combined immunodeficiency (SCID) is a life-threatening d

218 Early recognition of severe combined immunodeficiency (SCID) is a pediatric emergenc

219 Severe combined immunodeficiency (SCID) is a syndrome of divers

220 Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is caused by genetic va

221 Severe combined immunodeficiency (SCID) is characterized by arr

222 Severe combined immunodeficiency (SCID) is characterized by sev

223 essing SDF-1alpha were xenografted on severe combined immunodeficiency (SCID) mice.

224 oft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice.

225 by transfer of their splenocytes into severe combined immunodeficiency (SCID) mice.

226 In human artery-severe combined immunodeficiency (SCID) mouse chimeras, adoptiv

227 ant prolonged survival in a xenograft severe combined immunodeficiency (SCID) mouse model of dissemin

228 phagy in human skin xenografts in the severe combined immunodeficiency (SCID) mouse model of VZV path

229 RARalpha2-overexpressing MM tumors in severe combined immunodeficiency (SCID) mouse model.

230 at least a month in both nude rat and severe combined immunodeficiency (SCID) mouse xenograft models

231 onobese diabetic (NOD) mice, NOD with severe combined immunodeficiency (scid) mutation (SCID) mice, a

232 iver cells in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) or NOD/SCID/gammac(-/-)

233 nonimmunologic outcomes in cohorts of severe combined immunodeficiency (SCID) patients with either RA

234 H3 recognition were found mutated in severe combined immunodeficiency (SCID) patients.

235 Severe combined immunodeficiency (SCID) represents congenital d

236 um (PIDTC) is enrolling children with severe combined immunodeficiency (SCID) to a prospective natura

237 Newborn screening for severe combined immunodeficiency (SCID) using assays to detect

238 Severe combined immunodeficiency (SCID) with a complete absence

239 that impair Rag2 function can lead to severe combined immunodeficiency (SCID), a condition characteri

240 position found in some patients with severe combined immunodeficiency (SCID), and the double mutant

241 l reconstitution in many infants with severe combined immunodeficiency (SCID), but correction of B-ce

242 een identified, often associated with severe combined immunodeficiency (SCID), consistent with the re

243 to young horses (foals) affected with severe combined immunodeficiency (SCID), followed by challenge

244 cal profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefully def

245 vical spinal cords of adult mice with severe combined immunodeficiency (SCID), human pluripotent stem

246 ansplantation (HCT) for patients with severe combined immunodeficiency (SCID), including survival, T-

247 evant per se because in patients with severe combined immunodeficiency (SCID), infections caused by o

248 (ADA) deficiency, a cause of X-linked severe combined immunodeficiency (SCID), is a case in point.

249 und primary immunodeficiency disease, severe combined immunodeficiency (SCID), is fatal in infancy un

250 The most severe form, severe combined immunodeficiency (SCID), presents with profound

251 tural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndro

252 te lymphocyte development and lead to severe combined immunodeficiency (SCID), XLF mutations cause a

253 In a severe combined immunodeficiency (SCID)-hu murine model of huma

254 ssed the growth of MM in vivo using a severe combined immunodeficiency (SCID)-hu murine model.

255 in ORAI1 or STIM1 genes present with severe combined immunodeficiency (SCID)-like disease.

256 ansplantation (HSCT) in patients with severe combined immunodeficiency (SCID).

257 G) xenografts maintained in mice with severe combined immunodeficiency (SCID).

258 ion-based newborn screening (NBS) for severe combined immunodeficiency (SCID).

259 f adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

260 nation, hence loss of DNA-PK leads to severe combined immunodeficiency (SCID).

261 n-2 gamma-chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

262 e plasma in young horses (foals) with severe combined immunodeficiency (SCID).

263 gnificant proportion of patients with severe combined immunodeficiency (SCID).

264 ic metabolic disease characterized by severe combined immunodeficiency (SCID).

265 the generation of a marmoset model of severe combined immunodeficiency (SCID).

266 B-lymphocytes and are diagnosed with severe combined immunodeficiency (SCID).

267 rabian and 1 Arabian-pony cross) with severe combined immunodeficiency (SCID).

268 development, clinically presenting as severe combined immunodeficiency (SCID).

269 pathway result in radiation-sensitive severe combined immunodeficiency (SCID).

270 re injected intravenously into C.B-17 severe combined immunodeficiency (SCID)/beige (bg) mice.

271 immunodeficiencies including X-linked severe combined immunodeficiency (SCID-X1) and adenine deaminas

272 X-linked severe combined immunodeficiency (SCID-X1) caused by mutations

273 X-linked severe-combined immunodeficiency (SCID-X1) has been treated by

274 X-linked Severe Combined Immunodeficiency (SCID-X1) is a genetic disease

275 ials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine le

276 vectors for gene therapy of X-linked severe combined immunodeficiency (SCID-X1), we have evaluated n

277 hy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1).

278 use in a clinical trial for X-linked severe combined immunodeficiency (SCID-X1).

279 for the correction of canine X-linked severe combined immunodeficiency (SCID-X1).

280 in vivo in hairless outbred mice with severe combined immunodeficiency (SHO-Prkdc(scid)Hr(hr)).

281 phopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block in cent

282 nically mild initial presentation could be a combined immunodeficiency, so as to provide appropriate

283 A patient with multiorgan autoinflammation, combined immunodeficiency, subclinical amylopectinosis,

284 that inactivate Artemis cause a human severe combined immunodeficiency syndrome associated with cellu

285 mutations are responsible for a rare primary combined immunodeficiency syndrome associated with sever

286 inflammation, muscle weakness, and a severe combined immunodeficiency syndrome.

287 ast, hypomorphic Artemis mutations result in combined immunodeficiency syndromes of varying severity,

288 shed tumors (ie, in nonobese diabetic-severe combined immunodeficiencies) that were derived from CD44

289 We performed a multicenter survey of severe combined immunodeficiency transplantation centers in Nor

290 Recipient mice with severe-combined immunodeficiency underwent retrorsine treatment

291 h adenosine deaminase (ADA)-deficient severe combined immunodeficiency using 2 slightly different ret

292 anglion (DRG) xenografts in mice with severe combined immunodeficiency using multiscale correlative i

293 neutrophil infiltration in mice with severe combined immunodeficiency, which is accompanied by stron

294 l killer cell-sufficient patient with severe combined immunodeficiency, whom we found had mutations i

295 ciency should be considered in patients with combined immunodeficiency with B cell, T cell, and fibro

296 Combined immunodeficiency with multiple intestinal atres

297 ciency should be considered in patients with combined immunodeficiency with T-cell abnormalities.

298 tion in a clinical trial for X-linked severe combined immunodeficiency (X-SCID) has prompted safety c

299 X-linked severe combined immunodeficiency (X-SCID) is an immune disorder

300 ore immunity to infants with X-linked severe combined immunodeficiency (XSCID) caused by mutations in